Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia

Maria Ilaria Del Principe, Giovanni Del Poeta, Adriano Venditti, Francesco Buccisano, Luca Maurillo, Rita Marini, Maria Christina Cox, Paola Panetta, Giovanna Suppo, Massimo Degan, Antonio Bruno, Valter Gattei, Sergio Amadori

Research output: Contribution to journalArticlepeer-review


Background and Objectives. p53 status and CD38 antigen are biological factors influencing response to therapy and clinical course in B-cell chronic lymphocytic leukemia (B-CLL). This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis. Design and Methods. Wild and mutant forms of p53 protein were evaluated in 197 B-CLL patients at diagnosis or before progression by an immunoenzymatic method in plasma using an anti-p53 monoclonal antibody. CD38 expression was analyzed by a multicolor flow cytometric assay. Results. Higher levels of both soluble p53 (sp53) and CD38 were significantly correlated with intermediate and high Rai stages, with higher β2-microglobulin and soluble CD23 values, determined at diagnosis. Shorter overall survival (OS) and progression-free survival (PFS) were both observed in sp53+ and CD38+ patients (p 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance.

Original languageEnglish
Pages (from-to)1468-1475
Number of pages8
Issue number12
Publication statusPublished - Dec 2004


  • B-CLL
  • CD38
  • Prognosis
  • Soluble p53

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this